Teladoc Health, Inc. advances employer healthcare initiatives at San Diego conference
Teladoc Health, Inc. is participating in The Conference Board’s San Diego Employee Health Care Conference to engage with employer leaders on improving healthcare experiences, patient outcomes, and cost predictability. Following prior discussions in New York City, Teladoc Health aims to further strategic dialogue in the sector. The company has also recently expanded its offerings to include a Medicare virtual Diabetes Prevention Program and dietitian-led nutrition services, reflecting a focus on accessible care and long-term outcomes.
Why Teladoc Requires Patience at This Time: Buying Is Premature, Selling Is Unwise
Teladoc Health (TDOC) is a leading telemedicine provider with significant international operations, structured into Integrated Care and BetterHelp divisions. While the company faces challenges like slowing growth in BetterHelp and intense competition, it is proactively expanding services, integrating AI, and improving cost management, positioning it for potential long-term profitability. Investors are advised to be patient and monitor the company's progress before making investment decisions, with the stock currently holding a Zacks Rank #3 (Hold).
Why Teladoc Deserves Patience Now: Too Early to Buy, Too Risky to Sell
Teladoc Health (TDOC) currently holds a Zacks Rank #3 (Hold) due to a mix of growth potential and significant risks. While the company is expanding its services, leveraging AI, and showing improved financial discipline with declining expenses, its BetterHelp segment revenue is decreasing, and it faces intense competition. Investors are advised to wait and observe the stabilization of BetterHelp and overall growth trends before making investment decisions.
Teladoc (TDOC) up 3.2% since last earnings report: Can it continue?
This article analyzes Teladoc's stock performance following its last earnings report, noting a 3.2% increase. It discusses factors that could influence whether this positive trend can be sustained, providing insight into the company's financial momentum.
Teladoc (NYSE: TDOC) CAO sells shares to cover RSU tax withholding
Teladoc Health's Chief Accounting Officer, Joseph Ronald Catapano, reported a routine equity compensation event where 2,083 restricted stock units converted into common stock. To cover tax withholding obligations for this vesting, he sold 675 shares at $5.114 each. After these transactions, Catapano directly holds 10,249 common shares of Teladoc.
Teladoc (TDOC) director Susan R. Salka awarded 48,638 restricted stock units
Teladoc Health, Inc. director Susan R. Salka was granted 48,638 restricted stock units (RSUs) of Teladoc common stock. These RSUs represent a contingent right to receive one share of common stock upon vesting. The vesting schedule dictates that one-third of the RSUs will vest on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.
Grabar Law Office Investigates Claims on Behalf of Long-Term Investors of Teladoc Health, Inc. (TDOC) as Class Action Survives Motion to Dismiss
Grabar Law Office is investigating Teladoc Health, Inc. (TDOC) on behalf of long-term investors following a class action lawsuit that survived a motion to dismiss. The lawsuit alleges that Teladoc made false statements regarding BetterHelp's customer acquisition costs and seasonal performance, as these costs had reportedly increased significantly due to market saturation. Investors who purchased TDOC stock before July 28, 2023, and still hold shares are encouraged to contact Grabar Law Office for potential corporate reforms and financial recovery.
Teladoc Health proposes virtual care model to close gaps in patient engagement
Teladoc Health is promoting a virtual care model to address gaps in patient engagement and reduce healthcare costs, arguing that relying solely on urgent care leads to missed preventive opportunities. The company emphasizes ongoing patient-provider interaction through virtual means. Recent initiatives include a virtual Diabetes Prevention Program for Medicare patients and hybrid nurse models to improve staffing and care delivery.
Teladoc (TDOC) director Susan R. Salka files initial Form 3 ownership
Teladoc Health, Inc. director Susan R. Salka filed an initial Form 3 ownership report, indicating her new insider status. This filing serves as a baseline disclosure, showing no reportable share transactions or derivative positions at this time. It establishes her obligation for future reporting of any insider trading activities.
Grabar Law Office Investigates Claims on Behalf of Long-Term Investors of Teladoc Health, Inc. (TDOC) as Class Action Survives Motion to Dismiss
Grabar Law Office is investigating claims on behalf of long-term Teladoc Health, Inc. (NYSE: TDOC) investors, following a class action lawsuit surviving a motion to dismiss. The lawsuit alleges that Teladoc made misleading statements regarding BetterHelp's customer acquisition costs and seasonal performance. Shareholders who purchased TDOC shares before July 28, 2023, and still hold them, are encouraged to contact Grabar Law Office for potential corporate reforms and return of funds.
Pineal Capital Management Issues Open Letter to the Board of Teladoc Health, Inc.
Pineal Capital Management, a shareholder in Teladoc Health, has issued an open letter to the company's Board of Directors expressing concern over the undervalued stock and the slow pace of action regarding key strategic areas. The firm believes Teladoc is vulnerable to an opportunistic takeover and urges the board to implement a value-unlock plan focusing on cost efficiencies, a major share buyback program, and a strategic review including potential separation of its core businesses. Pineal Capital highlights strong near-term business tailwinds and the significant hidden value, particularly within Teladoc's mental health platform, which it believes the market currently undervalues.
Pineal Capital Urges Teladoc Health Board Changes
Pineal Capital Management has sent an open letter to Teladoc Health's board, advocating for significant changes to its leadership and strategic direction. The investment firm, which holds a substantial stake in Teladoc, believes the current board and management lack the necessary expertise to navigate the evolving telehealth market effectively. Pineal Capital is pushing for a shift from aggressive expansion to a focus on profitability and increased shareholder value, a move that could significantly impact the future of the telehealth industry.
Former AMN chief who led 26 acquisitions joins Teladoc board
Teladoc Health (NYSE: TDOC) has appointed Susan Salka, former president and CEO of AMN Healthcare, to its board of directors, effective March 30, 2026. Salka, who led 26 acquisitions and grew AMN Healthcare's revenue to over $5 billion, will serve on Teladoc's audit and compensation committees. Her appointment follows the retirements of two board members and is expected to bring significant healthcare leadership and M&A experience to Teladoc.
Hims & Hers Expands Personalized Digital Healthcare Platform
Hims & Hers is expanding its personalized digital healthcare platform by integrating diagnosis, treatment, and fulfillment through telehealth and data-driven approaches. The company is investing in AI, expanding into new specialties like hormone health, and broadening access through collaborations and acquisitions to deliver scalable, individualized care. Despite this expansion, HIMS' shares have underperformed the industry over the past year, and its 2026 earnings per share are projected to decline.
Teladoc Health Appoints Susan Salka, Experienced Healthcare Executive, to Its Board of Directors
Teladoc Health has announced the appointment of Susan Salka, former president and CEO of AMN Healthcare Services, to its board of directors. Ms. Salka brings over 33 years of experience in healthcare leadership and will serve on the board's audit and compensation committees. Her appointment follows the retirements of Eric Evans and Thomas McKinley, and she is expected to provide valuable insights for the company's future growth and strategic development in virtual care.
Veteran executive Susan Salka joins Teladoc Health (NYSE: TDOC) board
Teladoc Health (NYSE: TDOC) has appointed Susan R. Salka, former president and CEO of AMN Healthcare Services, to its board of directors, effective March 30, 2026. Ms. Salka will serve on the audit and compensation committees, bringing extensive healthcare leadership and financial expertise to the company. Her experience, including orchestrating 26 acquisitions and growing AMN's revenue to over $5 billion, is expected to contribute significantly to Teladoc Health's strategic growth and outcomes-focused care.
Teladoc Health appoints Susan Salka to board of directors By Investing.com
Teladoc Health has appointed Susan Salka, former president and CEO of AMN Healthcare Services, to its board of directors. Salka will serve on the audit and compensation committees, bringing extensive healthcare leadership and governance experience. This appointment follows board retirements and comes as Teladoc faces financial headwinds, with its stock down 27% year-to-date, though InvestingPro analysis suggests it may be undervalued.
Teladoc Adds Susan Salka to Expanded Board of Directors
Teladoc Health, Inc. has expanded its board of directors to nine members, appointing Susan R. Salka, former president and CEO of AMN Healthcare Services, as an independent director and audit committee financial expert. Salka's extensive experience in healthcare workforce solutions and M&A is expected to strengthen Teladoc's governance and support its growth in the virtual care market. Her appointment follows other board retirements and additions, signaling ongoing refreshment at the company.
Teladoc Health Appoints Susan Salka, Experienced Healthcare Executive, to Its Board of Directors
Teladoc Health has appointed Susan Salka, former president and CEO of AMN Healthcare Services, to its board of directors. Salka brings extensive leadership and governance experience in healthcare, having guided AMN Healthcare to significant growth and strategic success. Her appointment is expected to provide valuable insights into care delivery transformation and contribute to Teladoc Health's future growth.
Virtual nursing technology takes center stage as Teladoc Health, Inc. engages at AONL2026
Teladoc Health, Inc. is highlighting its virtual nursing and connected care models at the AONL2026 conference, aiming to enhance workforce safety and build integrated health systems. The company is engaging with healthcare leaders to empower nurse leadership and accelerate innovation through digital solutions. Teladoc's recent initiatives include expanding virtual care services for employee well-being and improving access to Medicare virtual Diabetes Prevention Programs for older adults and rural communities.
Teladoc Health Appoints Susan Salka, Experienced Healthcare Executive, to Its Board of Directors
Teladoc Health has appointed Susan Salka, former president and CEO of AMN Healthcare Services, to its board of directors. Salka brings extensive healthcare leadership and governance experience, having driven AMN Healthcare's growth to over $5 billion in revenue. She will serve on Teladoc Health's audit and compensation committees, contributing strategic and operational insights for the company's future growth in virtual care.
Direct To Patient Digital Market Is Going to Boom Rapidly | Teladoc Health • Amwell • HealthTap
Coherent Market Insights has released a report on the "Direct-to-Patient Digital Market" forecasting significant growth between 2026 and 2033. The report analyzes market percentage records, competition, geographic distribution, and growth potential, covering industry performance, risk assessment, and projected ROI. Key market players include Teladoc Health, Amwell, and HealthTap, with segmentation spanning chronic disease management, telehealth services, and remote patient monitoring.
Teladoc Health Inc Stock: Navigating Telehealth Challenges and Analyst Hold Consensus in 2026
Teladoc Health Inc. faces ongoing pressures in the telehealth sector, leading analysts to maintain a "Hold" rating despite the company's pioneering role in virtual healthcare. The company reported better-than-expected Q4 2025 earnings but has guided for negative EPS in 2026. Analysts are divided on its future, with strategic initiatives in AI and mental health seen as potential recovery catalysts for this NYSE-listed firm.
Teladoc Health, Inc. (NYSE:TDOC) Receives Consensus Rating of "Hold" from Analysts
Teladoc Health, Inc. (NYSE:TDOC) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $7.64, despite some recent upgrades. The company's Q4 earnings surpassed estimates, but it remains unprofitable and has issued a negative EPS outlook for Q1 and FY 2026. Insider selling by the CEO and significant institutional ownership are also noted.
Teladoc Health (TDOC) price target decreased by 19.34% to 7.16
This article reports a significant decrease in the price target for Teladoc Health (TDOC) by 19.34%, bringing it down to $7.16. The specific reasons or analyst responsible for this target reduction are not detailed in the provided content.
Precision Trading with Teladoc Health Inc. (TDOC) Risk Zones
This article provides a detailed analysis of Teladoc Health Inc. (TDOC) focusing on near, mid, and long-term outlooks. It highlights a strong sentiment in the near and mid-term but a weak long-term outlook, with support being tested. The analysis also presents specific precision trading strategies tailored to different risk profiles, including long and short positions and a momentum breakout strategy, all based on AI-generated signals for entry, target, and stop-loss levels.
Teladoc Health (TDOC) price target decreased by 19.34% to 7.16
The article states that Teladoc Health's (TDOC) price target has been decreased by 19.34% to 7.16. No further details are provided in the snippet.
Teladoc Health, Inc. faces scrutiny as virtual urgent care adoption hinges on first-visit resolution
Teladoc Health is facing increased scrutiny from plan sponsors regarding the effectiveness of its virtual urgent care services, particularly concerning first-visit resolution and the ability to manage complex cases. In response, Teladoc is highlighting advancements that allow its virtual teams to handle a broader range of complex health issues. This strategic focus aims to address the evolving expectations of health plans and employers to ensure telehealth remains a prioritized benefit.
Teladoc Health (NYSE:TDOC) Price Target Lowered to $7.00 at Barclays
Barclays has lowered its price target for Teladoc Health (NYSE: TDOC) from $8.50 to $7.00, maintaining an "equal weight" rating, as other firms also reduced their targets, resulting in a consensus "Hold" rating with an average target of $7.64. The company remains unprofitable with recent financial results showing negative EPS and a market capitalization of approximately $993 million. Insider activity includes CEO Charles Divita III selling over 27,000 shares, while institutional investors hold a significant portion of the stock.
Teladoc Health pilots bedside and virtual nurse model at AONL2026
Teladoc Health has announced a new hybrid care model at AONL2026, combining bedside and virtual nurses to address staffing shortages and boost retention in the healthcare sector. This initiative aims to improve care delivery by integrating in-person expertise with remote support. The company continues to expand its virtual care offerings, including partnerships with VSP Vision and a Medicare-focused virtual Diabetes Prevention Program.
Teledoc (TDOC) Gets a $7 Price Target From Barclays: Can It Double From Recent Lows?
Barclays has cut its price target for Teladoc (TDOC) to $7 from $8.50, maintaining an Equal Weight rating, despite the stock having recovered from its lows. The company's future growth hinges on the success of BetterHelp's transition to an insurance-based delivery model and the stabilization of Integrated Care membership. Achieving the $7 target, which implies a market capitalization of $1.25 billion, requires robust performance in BetterHelp's insurance scaling and overall profitability improvements.
Barclays Maintains Rating, Lowers Price Target for TDOC | TDOC S
Barclays has maintained an "Equal-Weight" rating for Teladoc Health (TDOC) but lowered its price target from $8.50 to $7.00. This adjustment reflects a 17.65% decrease and follows similar actions by other firms like JP Morgan and Oppenheimer, though Deutsche Bank upgraded TDOC to "Buy." The telehealth company's average target price from analysts is $6.95, suggesting a potential upside of 24.78% from its current price, while GuruFocus estimates a fair value of $9.15.
Teladoc (TDOC) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Teladoc (TDOC) experienced a dip, underperforming the broader market but showed a strong climb over the past month. Investors are anticipating its upcoming earnings report, with current estimates forecasting a decline in EPS and revenue year-over-year. Analysts have recently revised their EPS estimates upward, leading to a Zacks Rank of #3 (Hold) for the company.
Digital Health Market Is Going to Boom| Teladoc Health, American Well Corporation, and Doctor on Demand
The Digital Health market is projected to grow significantly from USD 350.42 billion in 2025 to USD 1,143.01 billion by 2032, at a CAGR of 18.4%. This growth is attributed to increasing demand, an expanding customer base, and technological advancements. A new report by Coherent Market Insights provides a comprehensive analysis of the market, including competitive landscape, segmentation, and global growth opportunities.
The Bull Case For Teladoc Health (TDOC) Could Change Following Mixed Guidance And Rising User Growth - Learn Why
Teladoc Health recently reported mixed financial results, with revenue slightly above expectations but next-quarter guidance falling short. Despite this, the company raised its full-year guidance and saw an 8.5% increase in its user base to 101.8 million. The article explores how Teladoc's strategic focus on BetterHelp and chronic care, alongside increasing platform reach, might reshape its investment narrative despite competitive pressures and near-term cautious guidance.
Teladoc Health (NYSE:TDOC) Share Price Crosses Above Fifty Day Moving Average - What's Next?
Teladoc Health (NYSE:TDOC) recently saw its share price cross above its 50-day moving average, trading as high as $5.53 before settling at $5.3450. Despite beating EPS and revenue estimates for the last quarter, the company remains unprofitable and issued negative guidance for Q1 and FY2026. Analysts have largely maintained a "Hold" rating, with many trimming their price targets for the stock.
The Bull Case For Teladoc Health (TDOC) Could Change Following Mixed Guidance And Rising User Growth - Learn Why
Teladoc Health reported mixed Q4 2025 and full-year 2025 results, with revenue slightly above analyst expectations but next-quarter guidance falling short. Despite a cautious near-term outlook, the company increased its full-year guidance and saw an 8.5% user base increase to 101.8 million. The article discusses how these factors, combined with ongoing investment in BetterHelp and chronic care, could reshape Teladoc's investment narrative and impact its path to profitability.
Telehealth Market Poised for Exceptional Growth at 31.81% CAGR
The global telehealth market is projected for exceptional and sustained growth at a 31.81% CAGR from 2026 to 2034, reaching USD 2,458,662.53 million by 2034. This expansion is driven by the increasing prevalence of chronic disorders, rapid smartphone adoption, and accelerating product development, with North America expected to dominate the market. Key technological trends include AI-powered clinical decision support, remote patient monitoring, and 5G-enabled telemedicine.
A Look At Teladoc Health’s Valuation After Mixed Revenue Beat And Guidance Update
Teladoc Health (TDOC) recently reported mixed earnings, with revenue slightly above expectations but weaker near-term guidance, leading to a recent share price lift despite a negative year-long return. While one narrative suggests the stock is overvalued at $5.00 due to compliance costs and legal risks, another view highlights its low P/S ratio compared to industry peers, implying a potential undervaluation by the market. Investors are encouraged to consider both perspectives and further research for investment decisions.
Teladoc Health Stock Analysis: Decline, Growth Stagnation, and Investment Outlook - News and Statistics
Teladoc Health (TDOC) has experienced a significant stock price decline of 31.6% over the last six months, trading at $5.44, primarily due to weak quarterly results and sluggish growth. The company's sales grew at a mere 1.7% compounded annual rate over the past three years, and average revenue per user (ARPU) declined by 8.5% annually over the last two years. Analysts expect revenue to stall, leading to concerns about demand and suggesting that the stock's reasonable 4.3x forward EV/EBITDA valuation is outweighed by its shaky fundamentals and downside risk.
A Look At Teladoc Health’s Valuation After Mixed Revenue Beat And Guidance Update
Teladoc Health (TDOC) recently reported mixed quarterly results, with slightly above-expected revenue but weaker near-term guidance, though its full-year outlook increased more than peers. While the most followed narrative suggests Teladoc is 12.2% overvalued at a fair value of $5.00 due to rising compliance costs and data privacy regulations, its current P/S ratio of 0.4x is considerably lower than the industry average, indicating a potential undervaluation based on market multiples. Investors are encouraged to consider both the growth potential of virtual care and the associated risks.
Teladoc Health (TDOC) Stock Forecast and Price Target 2026
The article provides a stock forecast and price target for Teladoc Health (TDOC) for 2026, based on analysis from 21 Wall Street equities research analysts. Analysts have a consensus "Hold" rating for TDOC, with an average price target of $7.72, suggesting a potential upside of 43.67% from its current price of $5.38. The report details individual analyst ratings, price target changes, and a comparison of Teladoc Health to other medical companies.
Q1 EPS Estimates for Teladoc Health Lifted by Zacks Research
Zacks Research has increased its Q1 2026 EPS estimate for Teladoc Health (NYSE:TDOC) to ($0.36) and its FY2026 estimate to ($0.99), indicating an expectation of improving profitability despite continued losses. Analyst sentiment for TDOC is mixed, with a consensus "Hold" rating and an average price target of $7.76, while CEO Charles Divita III recently sold a significant number of shares. The company's stock has been volatile, trading near $5.38.
Teladoc Health (TDOC) Is Up 6.6% After BetterHelp Turnaround Hopes And Analyst Upgrades - Has The Bull Case Changed?
Teladoc Health (TDOC) recently saw a 6.6% stock jump following upbeat Q4 2025 results and analyst upgrades, notably from Deutsche Bank and BofA Securities, driven by renewed optimism for its BetterHelp mental health unit. Analysts view BetterHelp's profitability and user trends as crucial catalysts for Teladoc's potential turnaround, though competitive pressures and a shift towards lower-margin insurance revenue still pose risks. Despite these challenges, Teladoc's narrative projects significant revenue and earnings growth by 2028, with some analysts forecasting a substantial upside to its current stock price.
Teladoc (TDOC) executive earns 15,596 performance stock units tied to 2025 results
Teladoc Health, Inc. President, U.S. Group Health, Kelly Bliss, was granted 15,596 performance stock units, each representing a contingent right to receive one share of TDOC common stock. These units vest one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments, and the award size was determined by the company's 2025 financial results. The filing also amended a prior Form 4 to correct an earlier reporting error and recorded the conversion of 5,198 performance stock units into common stock.
Us Telehealth Market Set to Witness Rapid Growth Through 2033 | Teladoc Health Inc., American Well Corporation
Coherent Market Insights has released a report forecasting rapid growth for the US Telehealth Market through 2033. The report, titled "Us Telehealth Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast, 2026-2033," provides a comprehensive analysis including market percentage records, competitive dynamics, regional performance, and long-term growth potential. It identifies key market players such as Teladoc Health Inc. and American Well Corporation, and segments the market by type (Real Time Telehealth, Store And Forward Telehealth, Remote Patient Monitoring) and application (Hospitals, Clinics, Home Healthcare).
Us Telemedicine Market Is Going to Boom Rapidly | Teladoc Health Inc., American Well Corporation
Coherent Market Insights has published a new research study on the Global "Us Telemedicine Market" forecast to 2033, analyzing market patterns, growth drivers, restraints, and future opportunities. The report segments the market by type, application, end-user, and region, identifying key players such as Teladoc Health Inc. and American Well Corporation. It offers insights into competitive landscapes, market share, and regional dynamics to aid businesses in strategic planning.
[144] Teladoc Health, Inc. SEC Filing
Teladoc Health, Inc. (TDOC) filed a Form 144, indicating proposed and recent sales of common stock by an affiliate. The filing details the sale of 27,731 restricted shares tied to a vesting event on March 10, 2026, and also records dispositions by Charles Divita of 17,138 shares on December 11, 2025, and 50,145 shares on March 2, 2026. The SEC filing provides comprehensive information regarding the issuer, filer, securities to be sold, and previous sales by the involved party.
TDOC SEC Filings - Teladoc Health Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Teladoc Health (TDOC) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It includes recent examples of 8-K filings and details about how Stock Titan enhances access to these documents with AI-powered summaries. The article also lists recent insider transactions and other financial data for Teladoc Health.
Teladoc (NYSE: TDOC) CEO gains new stock units and sells shares for taxes
Teladoc Health, Inc. CEO Charles DiVita III reported significant insider activity, including receiving 64,653 common shares from the conversion of restricted and performance stock units, and 43,703 new performance stock units. To cover tax withholding obligations related to these vesting events, DiVita sold 27,731 common shares at $5.49 each. Following these transactions, the CEO directly holds 364,784 Teladoc common shares.
